Immunoprecise Antibodies Ltd (IPA NASDAQ) stock market data APIs
$1.0652
0.04(3.8%)
as of July 2, 2025
Try our APIs with
free plan!
Immunoprecise Antibodies Ltd Financial Data Overview
Price chart is built with
Anychart
ImmunoPrecise Antibodies Ltd. operates as a techbio company. It leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies; and support the discovery and development of therapeutic antibodies. The company's contract research organizations services include B cell Select platforms that enable antibody screening directly from B cells, facilitating the analysis of a set of antibodies, as well as for screening compared to traditional technologies; phage display services that are based on building custom immune libraries from various species; DeepDisplay, a technology utilizing a combination of transgenic animal platforms; bispecific Abthena technology; antibody humanization services; affinity maturation services; antibody development services; protein manufacturing; and cell line development services of target proteins or antibodies. It is also involved in the development and licensing of antibody discovery platforms and related IP assets. The company was founded in 1983 and is headquartered in Austin, Texas.
Prev. Close
1.0652
Open
1.1053
High
1.1216
Low
0.9986
52 wk Range
0.27-1.16
Market Cap
48 511 K
Shares Outstanding
45 765 K
Revenue
23 998 K
EPS
-0.4619
Beta
0.216
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Immunoprecise Antibodies Ltd data using free add-ons & libraries
Get Immunoprecise Antibodies Ltd Fundamental Data
Immunoprecise Antibodies Ltd Fundamental data includes:
- Net Revenue: 23 998 K
- EBITDA: -12 541 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-12
- EPS/Forecast: -0.056
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Immunoprecise Antibodies Ltd News
New
ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT ® Technology
Follow-Up to June 5, 2025, Announcement Demonstrates Validated Vaccine Candidate with Strong Translational Potential AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise (NASDAQ: IPA), a leader in AI-driven...
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
ATLANTIC CITY, NJ / ACCESSWIRE / November 27, 2024 / DealFlow Events is pleased to announce the initial lineup of companies participating in The Microcap Conference, set for January 28-30 in Atlantic ...
10 Oversold Canadian Stocks To Buy
In this piece, we will take a look at ten oversold Canadian stocks to buy. If you want to skip an introduction to the Canadian economy and the stock market, then take a look at 5 Oversold Canadian Sto...
ImmunoPrecise Antibodies Invites Investors and Stakeholders to Exclusive Interview with Market Radius Research
VICTORIA, British Columbia, July 14, 2023--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), an AI-driven biotherapeutic research and technology, is delighted to e...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
